Comparative Review Uncovers Distinct Actions of GABA-Targeting Sedatives

Sedative-hypnotic agents are critical for managing conditions like insomnia, anxiety disorders, and certain seizure disorders. Many exert their effects by modulating GABA (gamma-aminobutyric acid) receptors, the brain's primary inhibitory neurotransmitter system. Despite their widespread use, a comprehensive comparative analysis of the distinct mechanisms, efficacy, and safety profiles of diverse GABAergic agents like flunitrazepam, GHB, phenibut, and selank has been notably absent, hindering optimized therapeutic choices.

Flunitrazepam (a potent benzodiazepine) demonstrated high affinity for GABA-A receptors, resulting in rapid onset of sedation and an 80% reduction in sleep latency in insomnia models compared to placebo. GHB primarily acted as a GABA-B receptor agonist, significantly increasing slow-wave sleep by 60% but also presenting a 2.5-fold higher risk of respiratory depression at supratherapeutic doses compared to phenibut. Phenibut, a derivative of GABA with both GABA-B agonist and some GABA-A activity, exhibited a 45% anxiolytic effect in rodent models and showed a 30% lower incidence of severe withdrawal symptoms upon abrupt cessation compared to flunitrazepam. Selank, a synthetic anxiolytic peptide, uniquely modulated GABA-A receptor activity via allosteric mechanisms (modulating receptor activity without binding to the primary site), demonstrating a 70% reduction in anxiety-like behaviors without significant sedative effects, thus distinguishing its profile from the other three agents. Overall, the review highlighted that flunitrazepam and GHB carried a 3-fold higher risk of dependence and abuse potential compared to phenibut and selank in long-term use scenarios, emphasizing critical safety considerations.